Geode Capital Management LLC Lowers Position in Kezar Life Sciences, Inc. (NASDAQ:KZR)

Geode Capital Management LLC cut its holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 89.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,570 shares of the company’s stock after selling 560,342 shares during the quarter. Geode Capital Management LLC owned approximately 0.91% of Kezar Life Sciences worth $447,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of KZR. Peapod Lane Capital LLC bought a new position in shares of Kezar Life Sciences in the fourth quarter worth approximately $833,000. BML Capital Management LLC purchased a new stake in Kezar Life Sciences during the 4th quarter valued at $327,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Kezar Life Sciences by 613.8% in the 4th quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock worth $80,000 after purchasing an additional 10,219 shares in the last quarter. 67.90% of the stock is owned by hedge funds and other institutional investors.

Kezar Life Sciences Stock Up 2.3 %

KZR stock opened at $4.50 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. The company has a market cap of $32.88 million, a price-to-earnings ratio of -0.34 and a beta of 0.61. The business’s 50-day moving average is $4.98 and its two-hundred day moving average is $6.22. Kezar Life Sciences, Inc. has a fifty-two week low of $3.62 and a fifty-two week high of $9.18.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, March 25th. The company reported ($2.77) earnings per share for the quarter, missing the consensus estimate of ($2.71) by ($0.06). As a group, analysts forecast that Kezar Life Sciences, Inc. will post -4.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, William Blair restated an “outperform” rating on shares of Kezar Life Sciences in a research note on Friday, February 28th.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.